Trial · NCT02187471
Results by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 112
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | -1.90 | Standard Error 0.135 | units on a scale | |
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | -2.64 | Standard Error 0.137 | units on a scale | |
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | -2.04 | Standard Error 0.138 | units on a scale | |
| Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | -2.30 | Standard Error 0.136 | units on a scale | |
| Number of Participants Who Answered Much Improved or Better in Patient Global Impression of Change at Week 13 Receiving DS-5565, Pregabalin, or Placebo | Placebo | 88 | Participants | ||
| Number of Participants Who Answered Much Improved or Better in Patient Global Impression of Change at Week 13 Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | 145 | Participants | ||
| Number of Participants Who Answered Much Improved or Better in Patient Global Impression of Change at Week 13 Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | 127 | Participants | ||
| Number of Participants Who Answered Much Improved or Better in Patient Global Impression of Change at Week 13 Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | 134 | Participants | ||
| Change From Baseline to Week 13 in Average Score on the Fibromyalgia Index Questionnaire (FIQ) in Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | -15.02 | Standard Error 1.198 | units on a scale | |
| Change From Baseline to Week 13 in Average Score on the Fibromyalgia Index Questionnaire (FIQ) in Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | -19.42 | Standard Error 1.222 | units on a scale | |
| Change From Baseline to Week 13 in Average Score on the Fibromyalgia Index Questionnaire (FIQ) in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | -16.61 | Standard Error 1.215 | units on a scale | |
| Change From Baseline to Week 13 in Average Score on the Fibromyalgia Index Questionnaire (FIQ) in Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | -20.44 | Standard Error 1.209 | units on a scale | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | 30% Responders | 122 | Participants | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | 30% Responders | 144 | Participants | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | 30% Responders | 121 | Participants | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | 30% Responders | 125 | Participants | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Placebo | 50% Responders | 68 | Participants | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | Pregabalin 150 mg BID | 50% Responders | 95 | Participants | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg QD | 50% Responders | 77 | Participants | |
| Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo | DS-5565 15 mg BID | 50% Responders | 89 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02187471/results